Bintrafusp alfa, the first-in-class bifunctional fusion protein TGF-β trap fused to a human immunoglobulin G1 antibody blocking PD-L1, had encouraging efficacy and manageable tolerability in patients with NSCLC previously treated with platinum. Here, TGFB1 is linked to non-small cell lung carcinoma.